PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more
Market Cap & Net Worth: PharmaEngine (4162)
PharmaEngine (TWO:4162) has a market capitalization of $244.93 Million (NT$8.10 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #16116 globally and #616 in its home market, demonstrating a -7.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaEngine's stock price NT$57.20 by its total outstanding shares 141677000 (141.68 Million).
PharmaEngine Market Cap History: 2015 to 2026
PharmaEngine's market capitalization history from 2015 to 2026. Data shows change from $603.70 Million to $244.93 Million (-7.41% CAGR).
PharmaEngine Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaEngine's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.15x
PharmaEngine's market cap is 0.15 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.22x
PharmaEngine's market cap is 0.22 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $603.70 Million | $507.24 Million | $394.02 Million | 1.19x | 1.53x |
| 2016 | $550.63 Million | $1.13 Billion | $689.62 Million | 0.49x | 0.80x |
| 2017 | $560.25 Million | $853.68 Million | $387.06 Million | 0.66x | 1.45x |
| 2018 | $421.50 Million | $293.43 Million | $129.36 Million | 1.44x | 3.26x |
| 2019 | $259.05 Million | $314.04 Million | $42.55 Million | 0.82x | 6.09x |
| 2020 | $220.51 Million | $1.06 Billion | $604.28 Million | 0.21x | 0.36x |
| 2021 | $288.71 Million | $654.84 Million | $426.03 Million | 0.44x | 0.68x |
| 2022 | $512.92 Million | $654.38 Million | $318.78 Million | 0.78x | 1.61x |
| 2023 | $443.82 Million | $767.67 Million | $274.65 Million | 0.58x | 1.62x |
| 2024 | $386.67 Million | $2.52 Billion | $1.75 Billion | 0.15x | 0.22x |
Competitor Companies of 4162 by Market Capitalization
Companies near PharmaEngine in the global market cap rankings as of March 19, 2026.
Key companies related to PharmaEngine by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PharmaEngine Historical Marketcap From 2015 to 2026
Between 2015 and today, PharmaEngine's market cap moved from $603.70 Million to $ 244.93 Million, with a yearly change of -7.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$244.93 Million | -18.75% |
| 2025 | NT$301.46 Million | -22.04% |
| 2024 | NT$386.67 Million | -12.88% |
| 2023 | NT$443.82 Million | -13.47% |
| 2022 | NT$512.92 Million | +77.66% |
| 2021 | NT$288.71 Million | +30.93% |
| 2020 | NT$220.51 Million | -14.88% |
| 2019 | NT$259.05 Million | -38.54% |
| 2018 | NT$421.50 Million | -24.77% |
| 2017 | NT$560.25 Million | +1.75% |
| 2016 | NT$550.63 Million | -8.79% |
| 2015 | NT$603.70 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PharmaEngine was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.93 Million USD |
| MoneyControl | $244.93 Million USD |
| MarketWatch | $244.93 Million USD |
| marketcap.company | $244.93 Million USD |
| Reuters | $244.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.